CA2341805C - Preparation de valproate de sodium a liberation controlee - Google Patents

Preparation de valproate de sodium a liberation controlee Download PDF

Info

Publication number
CA2341805C
CA2341805C CA002341805A CA2341805A CA2341805C CA 2341805 C CA2341805 C CA 2341805C CA 002341805 A CA002341805 A CA 002341805A CA 2341805 A CA2341805 A CA 2341805A CA 2341805 C CA2341805 C CA 2341805C
Authority
CA
Canada
Prior art keywords
valproate
formulation
weight percent
released
measurement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002341805A
Other languages
English (en)
Other versions
CA2341805A1 (fr
Inventor
Yihong Qiu
Richard P. Poska
Howard S. Cheskin
J. Daniel Bollinger
Kevin R. Engh
Sandeep Dutta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGP Products Operations GmbH
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/748,567 external-priority patent/US6511678B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CA2341805A1 publication Critical patent/CA2341805A1/fr
Application granted granted Critical
Publication of CA2341805C publication Critical patent/CA2341805C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Nouvelle formulation polymère à administrer par voie orale contrôlée adaptée à l'administration, en une fois par jour, de composés de valproate, tels que du sodium de divalproex. Cette formulation présente des avantages importants par rapport aux formulations de valproate à libération lente de la technique antérieure. Cette formulation réduit au minimum la variation entre des concentrations plasmatiques maximales et minimales de valproate sur une période de dosage de 24 heures. Cette formulation suit un modèle de libération d'ordre zéro, produisant ainsi des concentrations plasmatiques sensiblement uniformes de valproate, une fois que des concentrations plasmiques d'équilibre ont été obtenues. Grâce à cela, on obtient une incidence considérablement inférieure des effets secondaires chez les patients consommant une telle formulation.
CA002341805A 2000-12-22 2001-03-23 Preparation de valproate de sodium a liberation controlee Expired - Lifetime CA2341805C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/748,567 2000-12-22
US09/748,567 US6511678B2 (en) 1998-12-18 2000-12-22 Controlled release formulation of divalproex sodium

Publications (2)

Publication Number Publication Date
CA2341805A1 CA2341805A1 (fr) 2001-09-19
CA2341805C true CA2341805C (fr) 2003-12-16

Family

ID=25009990

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341805A Expired - Lifetime CA2341805C (fr) 2000-12-22 2001-03-23 Preparation de valproate de sodium a liberation controlee

Country Status (1)

Country Link
CA (1) CA2341805C (fr)

Also Published As

Publication number Publication date
CA2341805A1 (fr) 2001-09-19

Similar Documents

Publication Publication Date Title
US20040156898A1 (en) Controlled release formulation of divalproex sodium
JP4219988B2 (ja) 高いバイオアベイラビリティーを有するフェノフィブレート医薬組成物及びそれを調製するための方法
US6528090B2 (en) Controlled release formulation of divalproex sodium
JP2519296B2 (ja) イブプロフェン除放性錠剤及びその製造方法
EP1140034B1 (fr) Preparation a liberation controlee de divalproex sodium
JPH07558B2 (ja) モピダモール製剤
US6713086B2 (en) Controlled release formulation of divalproex sodium
JP2015147812A (ja) 口腔内崩壊錠の製造方法
US6720004B2 (en) Controlled release formulation of divalproex sodium
JP2009501801A (ja) イブプロフェンとファモチジンとを含有する医薬およびその投与
JP2005508901A (ja) 活性成分を徐放する剤形
JP2005533774A (ja) ジバルプロエクスソジウムの放出遅延剤
US20070160667A1 (en) Controlled release formulation of divalproex sodium
CA2341805C (fr) Preparation de valproate de sodium a liberation controlee
WO2009008004A2 (fr) Formulations à libération prolongée de divalproex de sodium
WO2002051402A1 (fr) Controlled release formulation of divalproex sodium
US20020025341A1 (en) Controlled release formulation of divalproex sodium
US20020031549A1 (en) Controlled release formulation of divalproex sodium
EP1815850B1 (fr) Formulation à libération contrôlée comprenant acide valproique et ses dérivés
US20080081069A1 (en) Novel controlled release formulations of divalproex sodium
CA2341803C (fr) Preparation de valproate de sodium a liberation controlee
WO2007081341A1 (fr) Formule à libération contrôlée d'acide divalproïque et ses dérivés
CN115463104A (zh) 一种含有ebtp的片剂及其制备方法
WO2023182332A1 (fr) Composition d'additifs pour comprimés orodispersible
AU2004210543A1 (en) Controlled release formulation of divalproex sodium

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210323

MKEX Expiry

Effective date: 20210323